The microbiome testing company is expanding its research, clinical and B2B ambitions across the lifespan, including work spanning vaginal health, fertility, pregnancy and menopause.
The big question (as exciting as these two very rare Series B raises in women's health are) is "so what?" You can evaluate the microbiome but what do you do about it? Not a single product on the market has been shown to effectively alter the vaginal microbiome. (Obviously that is something we are working on). Watch this space!
Fifty-four babies, 6% against 29%. That is a big gap from a small trial, and the researcher saying it only justifies a second trial is the right size for it. Menopause is on the roadmap now, so I'd like to see whether those services get a first trial of their own before they are sold.
The eczema result is genuinely striking - the 6% v 29% in the intervention arm. Fifty-four babies is enough to justify a second trial but it's not enough to call this settled, which is the exact gap I keep running into with GLP-1 evidence in PMOS too.
The big question (as exciting as these two very rare Series B raises in women's health are) is "so what?" You can evaluate the microbiome but what do you do about it? Not a single product on the market has been shown to effectively alter the vaginal microbiome. (Obviously that is something we are working on). Watch this space!
Fifty-four babies, 6% against 29%. That is a big gap from a small trial, and the researcher saying it only justifies a second trial is the right size for it. Menopause is on the roadmap now, so I'd like to see whether those services get a first trial of their own before they are sold.
The eczema result is genuinely striking - the 6% v 29% in the intervention arm. Fifty-four babies is enough to justify a second trial but it's not enough to call this settled, which is the exact gap I keep running into with GLP-1 evidence in PMOS too.
Great to see a second RCT is already underway!!